文献速递肾小球疾病慢性肾脏病

欧洲肾脏协会免疫肾病工作组提出疾病修饰抗肾病药物定义

Disease-modifying anti-nephropathic drugs (DMANDs)-a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA).
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

欧洲肾脏协会免疫肾病工作组提出免疫介导性肾小球肾炎和足细胞病的疾病修饰三大关键标准:最小化疾病活动、防止肾脏结构和功能丧失、减少治疗相关毒性。药物须同时满足三条才能称为疾病修饰抗肾病药物(DMAND),且该状态在监管批准时可能不明确。CKD方面需单独考虑和治疗,例如RAS抑制剂对CKD方面是DMAND但对免疫疾病本身不是。

要点

  • DMAND需同时满足三大标准:最小化疾病活动、防止肾脏结构和功能丧失、减少治疗相关毒性。
  • 药物在监管批准时其DMAND状态可能不明确,需后续评估。
  • 免疫介导性肾病中CKD方面需单独治疗,RAS抑制剂对CKD是DMAND但对免疫疾病本身不是。

核心结论

  • 提出了免疫介导性肾小球肾炎和足细胞病中疾病修饰的三个关键标准,药物须全部满足才能称为DMAND。
  • 定义DMAND有助于为未来治疗策略设定优先级,可能意味着更快速减量或避免非选择性免疫抑制剂。

研究设计与样本

  • 欧洲肾脏协会免疫肾病工作组提出的定义性文件,基于专家共识提出三条关键标准。

主要发现

  • 疾病修饰的三个关键标准为:最小化疾病活动、防止肾脏结构和功能丧失、减少治疗相关毒性。
  • 药物须满足全部三条标准才能视为DMAND,其状态在监管批准时可能不明确。
  • 免疫介导性肾病中CKD方面须单独考虑和治疗,RAS抑制剂对CKD方面是DMAND但对免疫疾病本身不是。
  • 非选择性免疫抑制剂携带短期致畸性和长期恶性肿瘤风险。

关键数值与推荐

  • DMAND须同时满足:最小化疾病活动、防止肾脏结构和功能丧失、减少治疗相关毒性。
  • RAS抑制剂对免疫介导性肾病的CKD方面是DMAND,但对免疫疾病本身不是。

临床怎么用

  • 临床中应区分免疫疾病本身和CKD方面的治疗,RAS抑制剂可用于CKD方面但非免疫疾病本身。
  • 未来治疗策略可能更快速减量或避免非选择性免疫抑制剂,转向保护GFR和减缓下降并消除长期毒性。

局限性

  • 该定义为专家提议,DMAND状态在监管批准时可能不明确,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A definition of 'disease modification' for kidney disease is long overdue. Here, we propose three key criteria for disease modification in immune-mediated glomerulonephritis and podocytopathies: minimizing disease activity, preventing loss of kidney structure and function, and reducing treatment-related toxicity. To be considered a disease-modifying anti-nephropathic drug (DMAND), a drug must fulfil all three criteria, hence the DMAND status of a drug may not be clear at the time of regulatory approval. Notably, the aspect of chronic kidney disease (CKD) in immune-mediated kidney diseases must be considered and treated separately, e.g. renin-angiotensin system inhibitor is a DMAND for the CKD aspect but not for the immune disease itself. Defining DMANDs is an ambitious goal but one that may help to set the priorities for future treatment strategies in immune-mediated kidney disease. This may mean much more rapid tapering or even avoidance of unselective, non-targeted immunosuppressive agents, which carry considerable short (teratogenicity) and long term risks (malignancies). The criteria proposed here set a high bar for 'disease modification' in immune-mediated kidney disease. Inevitably, this must dictate altered priorities with the focus for new therapeutic agents and strategies shifting from solely reduction of proteinuria to preservation of GFR and attenuation of decline, whilst also eliminating long-term toxicity.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Teng YKO, Frangou E, Kronbichler A, et al. Disease-modifying anti-nephropathic drugs (DMANDs)-a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA). Nephrol Dial Transplant. 2025. PMID: 39924173. doi:10.1093/ndt/gfaf033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。